intraoperative stroke. There were no deaths or aneurysm ruptures as a result of a missed finding on the 1-month DU examination.
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National Trends for Operative Management of Uncomplicated Type B Aortic Dissection
David N. Blitzer, Raghuveer Vallabhaneni. MedStar Health, Baltimore, Md
Objective: Traditionally, management for uncomplicated type B aortic dissection (TBAD) has been primarily medical, focusing on blood pressure control. Recent literature supports considering thoracic endovascular aortic repair to seal the proximal entry tear, possibly decreasing longterm morbidity and mortality by favorably remodeling the aorta. We used the Nationwide Inpatient Sample (NIS) to evaluate trends in the management of uncomplicated TBAD.
Methods: Data were collected through the NIS from 2004 to 2014. Patients were identified who had a primary diagnosis of thoracic or thoracoabdominal aortic dissection during nonelective hospitalization. Exclusion criteria consisted of procedure codes indicative of type A aortic dissection (cardioplegia, valve repair, and operations on vessels of the heart), aortic aneurysm, and complicated TBAD (eg, malperfusion syndrome). Our independent variable of interest was operative management (OM) vs medical management (MM). Data were weighted according to discharge weights provided in the NIS and analyzed using the independent samples t-test or Pearson c 2 for continuous and categorical data, respectively. Simple linear regression was used to determine the trend in management over time. Statistical significance was determined by a < .05.
Results: Final analyses included 48,946 patients during the 11-year period (OM, 12, 838 patients; MM, 36, 118 patients) . OM and MM demographic data significantly differed with regard to demographic variables (Table) , including age (OM: median, 62 [interquartile range (IQR), 52-73] years; MM: median, 68 [IQR, years), sex (OM: female, 40%; MM, female, 48%), and hospital bed size (OM: 80% large, 15% medium, 5% small; MM: 73% large, 20% medium, 7% small); however, they were not significantly different regarding race or hospital region. In addition, OM had significantly lower mortality (OM, 10%; MM, 12%; P < .05) and a longer length of stay (OM: median, 9 [IQR, (6) (7) (8) (9) (10) (11) (12) (13) (14) Objective: The advent of fenestrated endovascular devices expanded anatomic eligibility for endovascular aneurysm repair (EVAR) for abdominal aortic aneurysms. The Zenith fenestrated endograft (ZFEN; Cook Medical, Bloomington, Ind) was approved by the Food and Drug Administration in 2012. We compared the perioperative outcomes of patients treated with ZFEN with those of patients treated with standard infrarenal EVAR.
Methods: We identified patients who underwent EVAR for elective or symptomatic abdominal aortic aneurysms within the American College of Surgeons National Surgical Quality Improvement Program vascular targeted module between 2011 and 2016. We compared all patients e110 Abstracts
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June 2018 treated with the ZFEN device with those treated with standard infrarenal EVAR. Primary outcomes were 30-day mortality, and secondary outcomes included procedural characteristics and occurrence of any postoperative complication registered within the database. To account for baseline differences, we calculated propensity scores and employed inverse probability-weighted logistic regression. Results: We identified 189 ZFEN cases and 6717 infrarenal EVARs. Baseline characteristics were similar between both groups, except for clinical presentation with acute preoperative renal failure (ZFEN, 1.1%; EVAR, 0.1%; P ¼ .014). Thirty-day mortality was comparable between ZFEN and EVAR (2.1% vs 0.9%, respectively; P ¼ .1). For patients treated with ZFEN, median operative time was almost twice as long (224 vs 120 minutes; P < .001), intraoperative and postoperative transfusions occurred more often (19.6% vs 5.8%; P < .001), and length of stay was longer (median, 2 vs 1 day; P < .001). There was no significant difference in the rate of any postoperative complications (11.1% vs 8.0%; P ¼ .14). After propensity weighting, ZFEN was associated with higher 30-day mortality (odds ratio, 3.1; 95% confidence interval, 1.1-8.7; P ¼ .035) but not complications (odds ratio, 1.5; 95% confidence interval, 0.9-2.5; P ¼ .085).
Conclusions: In this study, ZFEN was associated with higher adjusted 30-day mortality, longer procedure times, higher transfusion rates, and longer length of stay than standard infrarenal EVAR. Although residual confounding due to the application of ZFEN to more complex anatomy may explain many of these differences, more data are needed on the safety of ZFEN.
Author Disclosures: C. Li: Nothing to disclose; P. Liang: Nothing to disclose; T. F.X. O'Donnell: Nothing to disclose; A. B. Pothof: Nothing to disclose; M. L. Schermerhorn: Abbott: Consulting fees (eg, advisory boards), Bolton: Consulting fees (eg, advisory boards), Cook: Consulting fees (eg, advisory boards), Endologix: Consulting fees (eg, advisory boards); N. J. Swerdlow: Nothing to disclose; R. Varkevisser: Nothing to disclose; H. Verhagen: Medtronic, W. L. Gore, Endologix Arsenal AAA: Consulting fees (eg, advisory boards). Objective: Mortality benefits of statin use in open and endovascular abdominal aortic aneurysm repair have been well documented. In this study, we sought to examine the effects of statin use on the outcomes of thoracic endovascular aortic repair (TEVAR).
IP085.
Effects of Statin Use on Endovascular Repair of Thoracic Aortic Aneurysm and Dissection
Methods: The Vascular Quality Initiative data set was retrospectively queried to identify all patients who underwent TEVAR from 2010 to 2017. Univariate (c 2 test, t-test) and multivariate (logistic regression) methods were employed to evaluate the effects of statin use on postoperative outcomes after TEVAR.
Results: A total of 9147 patients underwent TEVAR, of whom 55% were taking statins. Patients taking statins were older (mean age [standard deviation], 71.4 [10.1] years vs 62.2 [17.0] years) and were more likely to be male (66% vs 63%) and white (79% vs 69%; all P < .001). The comorbidities were also significantly higher among statin users (Table I) . Statin users were more likely to be asymptomatic at presentation (67.4% vs 41.7%) and to undergo elective TEVAR (79.9% vs 55.7%), whereas nonstatin users were more likely to be symptomatic (49% vs 29%), to present with ruptured aneurysm (10% vs 4%), and to undergo urgent (24% vs 13%) and emergent (20% vs 7%) repair (all P < .001). Aortic dissection (32% vs 18%) was higher in nonstatin users, whereas aneurysm (66.9% vs 41.3%) was higher among statin users (P < .001). The total length of hospital stay (mean [standard deviation], 8.9 [23.3] 6] days; P < .001) was significantly lower in statin users. In the aneurysm group, 30-day mortality (5.8% vs 6.4%), cardiac (10.3% vs 11.2%), stroke (5.3% vs 5.2%), spinal cord ischemia (8.0% vs 8.6%), and intestinal ischemic complications (2.2% vs 1.6%) were similar between the two groups (all P > .05). However, in patients with dissection, postoperative mortality (4.9% vs 7.5%) and any major postoperative complication (23.9% vs 31.1%) including dialysis (2.7% vs 5.6 %) and intestinal ischemic complications (1.6% vs 3.5%) were significantly lower in statin vs nonstatin users (all P < .05). After adjustment for potential confounders, compared with nonstatin users, patients taking statins had 37% reduction in 30-day mortality (odds ratio [OR] 
